(Q30318822)

12 October 2017

1 reference

title

Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management (English)

1 reference

12 October 2017

0 references

0 references

1 reference

Alexander Stein

1

1 reference

PMCID

3126005

12 October 2017

Wieland Voigt

series ordinal

2

1 reference

PMCID

3126005

12 October 2017

Karin Jordan

series ordinal

3

1 reference

12 October 2017

1 January 2010

1 reference

Therapeutic advances in medical oncology

12 October 2017

1 reference

12 October 2017

2

1 reference

12 October 2017

51-63

1 reference

12 October 2017

1

1 reference

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

12 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Chemotherapy-induced diarrhoea.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Does celecoxib have a role in the treatment of patients with colorectal cancer?

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Irinotecan-induced mucositis is associated with changes in intestinal mucins

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Gastrointestinal complications of oncologic therapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CA

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Sorafenib in advanced hepatocellular carcinoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Intestinal mucositis: mechanisms and management

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Insights, challenges, and future directions in irinogenetics

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Should DPD analysis be required prior to prescribing fluoropyrimidines?

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Mucosal injury from targeted anti-cancer therapy.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Phase II study of activated charcoal to prevent irinotecan-induced diarrhea

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Gastrointestinal mucositis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Practical management of patients with chronic myeloid leukemia receiving imatinib

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Increased gastrointestinal absorption of large molecules in patients after 5-fluorouracil therapy for metastatic colon carcinoma.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Control of irinotecan-induced diarrhea by octreotide after loperamide failure

3 June 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Phase III Double-Blind Study of Glutamine Versus Placebo for the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Clinical trial: prophylactic intravenous alanyl-glutamine reduces the severity of gastrointestinal toxicity induced by chemotherapy--a randomized crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Neomycin as secondary prophylaxis for irinotecan-induced diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Activated charcoal to prevent irinotecan-induced diarrhea in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Oral and intestinal microflora in 5-fluorouracil treated rats, translocation to cervical and mesenteric lymph nodes and effects of probiotic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Octreotide in the treatment of severe chemotherapy-induced diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1758834009355164

Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

[Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats].

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3126005

Octreotide Acetate in the Treatment of Fluorouracil-Induced Diarrhea

26 November 2018

1 reference

12 December 2020

Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea

1 reference

12 December 2020

Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports

1 reference

12 December 2020

1 reference

12 December 2020

Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients

1 reference

12 December 2020

High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients

1 reference

12 December 2020

Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy

1 reference

12 December 2020

Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis

1 reference

12 December 2020

Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer

1 reference

12 December 2020

The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study

1 reference

12 December 2020

Effect of a glutamine-supplemented enteral diet on methotrexate-induced enterocolitis

1 reference

12 December 2020

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

12 December 2020

Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats

1 reference

12 December 2020

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803

1 reference

12 December 2020

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters

1 reference

12 December 2020

Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: dose finding study and evaluation of efficacy

1 reference

12 December 2020

Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial

1 reference

12 December 2020

Identifiers

DOI

10.1177/1758834009355164

1 reference

12 October 2017

1 reference

12 October 2017

1 reference

PMCID

3126005